Focused metabolomic profiling in the drug development process: advances from lipid profiling

Area of Science:

• Biotechnology
• Drug Development
• Analytical Chemistry

Background:

• 'Omics' technologies (genomics, transcriptomics, proteomics) promised to enhance drug development.
• These 'omics' have largely failed due to high false positive rates, impeding reliable decision-making.
• Metabolomics faces similar challenges but offers potential when implemented effectively.

Purpose of the Study:

• To evaluate the utility of metabolomics in drug development.
• To highlight the advantages of focused metabolomics platforms.
• To identify lipid profiling as a key area within focused metabolomics.

Main Methods:

• Analysis of data quality and false discovery rates in various 'omics' technologies.
• Development and application of focused metabolomics platforms.
• Assessment of lipid profiling techniques for sensitivity and reliability.

Main Results:

• Genomics, transcriptomics, and proteomics frequently produce unreliable results due to false positives.
• Focused metabolomics platforms can significantly minimize false discoveries and maximize sensitivity.
• Lipid profiling is a well-established focused metabolomics area demonstrating reliable data generation.

Conclusions:

• Effective implementation of metabolomics, particularly focused approaches, can overcome the limitations of other 'omics' technologies.
• Focused metabolomics provides reliable knowledge crucial for improving drug development decision-making.
• Lipid profiling exemplifies the successful application of focused metabolomics for robust scientific insights.